The estimated Net Worth of Andrew Booth is at least $31.1 Million dollars as of 26 May 2023. Mr Booth owns over 14,500 units of AbCellera Biologics stock worth over $411,570 and over the last 3 years he sold ABCL stock worth over $30,600,000. In addition, he makes $130,106 as Chief Financial Officer at AbCellera Biologics.
Mr has made over 7 trades of the AbCellera Biologics stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 14,500 units of ABCL stock worth $99,325 on 26 May 2023.
The largest trade he's ever made was selling 1,200,000 units of AbCellera Biologics stock on 9 June 2021 worth over $30,600,000. On average, Mr trades about 311,700 units every 72 days since 2021. As of 26 May 2023 he still owns at least 153,000 units of AbCellera Biologics stock.
You can see the complete history of Mr Booth stock trades at the bottom of the page.
Andrew Booth is the Chief Financial Officer at AbCellera Biologics.
As the Chief Financial Officer of AbCellera Biologics, the total compensation of Mr Booth at AbCellera Biologics is $130,106. There are 4 executives at AbCellera Biologics getting paid more, with Tryn T. Stimart Esq., J.D. having the highest compensation of $635,635.
Mr Booth is 47, he's been the Chief Financial Officer of AbCellera Biologics since . There are 2 older and 4 younger executives at AbCellera Biologics. The oldest executive at AbCellera Biologics Inc. is Tryn T. Stimart Esq., 51, who is the Chief Legal Officer & Corp. Sec..
Andrew's mailing address filed with the SEC is C/O ABCELLERA BIOLOGICS INC, 2215 YUKON STREET, VANCOUVER, A1, .
Over the last 4 years, insiders at AbCellera Biologics have traded over $394,042,033 worth of AbCellera Biologics stock and bought 6,630,906 units worth $88,015,834 . The most active insiders traders include Peter Thiel, Andrew Lo, and Holdings Ltd. Thermopylae. On average, AbCellera Biologics executives and independent directors trade stock every 23 days with the average trade being worth of $1,381,181. The most recent stock trade was executed by Holdings Ltd. Thermopylae on 29 August 2024, trading 283,516 units of ABCL stock currently worth $739,977.
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
AbCellera Biologics executives and other stock owners filed with the SEC include: